Boehringer Ingelheim Taps Beijing Friendship Hospital for MASH Trials – Expands China Key Initiative
Boehringer Ingelheim announced at the 8th China International Import Expo (CIIE) that it has signed...
Boehringer Ingelheim
Boehringer Ingelheim Licenses Pre‑Clinical Small‑Molecule Program from Kyowa Kirin for Autoimmune Therapy
Boehringer Ingelheim announced a licensing deal to acquire exclusive worldwide rights to a promising first‑in‑class...
Boehringer Ingelheim’s Nerandomilast Approved by China NMPA for Idiopathic Pulmonary Fibrosis
Boehringer Ingelheim announced that its oral selective phosphodiesterase‑4B (PDE4B) inhibitor Nerandomilast (JASCAYD®) has received formal...
Boehringer Ingelheim & AimedBio Announce Global ADC Collaboration to Target Broad‑Spectrum Cancers
Boehringer Ingelheim today disclosed a worldwide collaboration and licensing agreement with AimedBio to develop a...
Boehringer Ingelheim Secures FDA Approval for Nerandomilast (JASCAYD) in Idiopathic Pulmonary Fibrosis
Boehringer Ingelheim (BI) announced today that the U.S. Food and Drug Administration (FDA) has approved...
Boehringer Ingelheim & Sino Biopharma Secure Conditional Approval for Zongertinib in China
In a joint announcement, Boehringer Ingelheim (BI) and Sino Biopharmaceutical Limited (HKG: 1177) confirmed that the...
Boehringer Ingelheim’s HERNEXEOS Receives FDA Accelerated Approval for NSCLC Treatment
German pharmaceutical giant Boehringer Ingelheim (BI) announced that its HERNEXEOS (zongertinib tablets) has received accelerated...
Boehringer Ingelheim and Re-Vana Partner to Develop First-in-Class Ocular Therapies
German pharmaceutical giant Boehringer Ingelheim (BI) today announced a strategic collaboration and licensing agreement with...
Boehringer Ingelheim Reports 6.3% Sales Growth in First Half of 2025
Boehringer Ingelheim announced today its financial results for the first half of 2025, reporting group...
Boehringer Ingelheim Licenses Spevigo to LEO Pharma for Global Dermatology Expansion
German pharmaceutical giant Boehringer Ingelheim (BI) this week announced a licensing agreement with Denmark-based dermatology...
Boehringer Ingelheim Starts Phase III THULITE Study for BI 1815368 in Diabetic Macular Edema
German pharmaceutical major Boehringer Ingelheim announced the initiation of the Phase III THULITE study to...
Boehringer Ingelheim and Echosens Expand Partnership to Tackle MASH
Germany-based Boehringer Ingelheim and France-based Echosens have expanded their partnership to enhance early screening, precise...
Boehringer Ingelheim’s Metalyse Approved in China for Acute Ischemic Stroke
Germany-based pharmaceutical leader Boehringer Ingelheim announced receiving marketing approval from China’s National Medical Products Administration...
Boehringer Ingelheim and Tempus Forge Multi-Year AI-Driven Oncology Drug Development Partnership
Germany-based pharmaceutical major Boehringer Ingelheim has entered into a multi-year strategic collaboration with Tempus (NASDAQ:...
Boehringer Ingelheim’s Nerandomilast Filing Accepted for Review in Progressive Pulmonary Fibrosis
Boehringer Ingelheim announced that the Center for Drug Evaluation (CDE) of China’s National Medical Products...
Boehringer Ingelheim’s Zongertinib Shows Promising Results in HER2-Mutant NSCLC Trial
German pharmaceutical giant Boehringer Ingelheim has released the latest results from the Beamion LUNG-1 trial,...
Boehringer Ingelheim Biopharmaceuticals (China) Completes PMDA GMP Inspection for Japan Market Supply
German pharmaceutical leader Boehringer Ingelheim (BI) announced that its Shanghai-based subsidiary, Boehringer Ingelheim Biopharmaceuticals (China)...
Boehringer Ingelheim Partners with Tessellate Bio on ALT Cancer Therapies
Boehringer Ingelheim (BI), a German pharmaceutical leader, has entered into a strategic collaboration and global...
Boehringer Ingelheim Partners with Cue Biopharma to Advance CUE-501 for Autoimmune Diseases
Germany’s Boehringer Ingelheim (BI) has entered into a strategic agreement with US-based Cue Biopharma, Inc....
Salipro Biotech and Boehringer Ingelheim Collaborate on Drug Development for Membrane Proteins
Sweden-based Salipro Biotech AB announced a research and license agreement with German pharmaceutical giant Boehringer...